Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Neurogene (NGNE) EBITDA Margin (2019 - 2025)

Historic EBITDA Margin for Neurogene (NGNE) over the last 6 years, with Q1 2025 value amounting to 32398.75%.

  • Neurogene's EBITDA Margin rose 292793100.0% to 32398.75% in Q1 2025 from the same period last year, while for Sep 2025 it was 121637.5%, marking a year-over-year increase of 1451130400.0%. This contributed to the annual value of 8930.27% for FY2024, which is N/A changed from last year.
  • As of Q1 2025, Neurogene's EBITDA Margin stood at 32398.75%, which was up 292793100.0% from 2176.65% recorded in Q2 2024.
  • Neurogene's EBITDA Margin's 5-year high stood at 434500.0% during Q1 2023, with a 5-year trough of 2176.65% in Q2 2024.
  • For the 3-year period, Neurogene's EBITDA Margin averaged around 116960.38%, with its median value being 17759.09% (2025).
  • As far as peak fluctuations go, Neurogene's EBITDA Margin tumbled by 2000000000bps in 2024, and later soared by 292793100bps in 2025.
  • Neurogene's EBITDA Margin (Quarter) stood at 434500.0% in 2023, then plummeted by -101bps to 2176.65% in 2024, then surged by 1588bps to 32398.75% in 2025.
  • Its EBITDA Margin stands at 32398.75% for Q1 2025, versus 2176.65% for Q2 2024 and 3119.44% for Q1 2024.